Hidden biases in an observational study of bevacizumab beyond progression

Journal of Clinical Oncology

Volumn 27, Issue 10, 2009, Pages 1732-1733

  Kopetz, Scott ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; IRINOTECAN; ONDANSETRON; OXALIPLATIN;

CANCER GROWTH; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COLORECTAL CANCER; DRUG EFFICACY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MEDICAL DECISION MAKING; NAUSEA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIAS (EPIDEMIOLOGY); COLORECTAL NEOPLASMS; DISEASE PROGRESSION; EPIDEMIOLOGIC RESEARCH DESIGN; PHYSICIAN'S PRACTICE PATTERNS;

EID: 63749114837     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.2084     Document Type: Letter

References (2)

1. Grothey A, Sugrue M, Purdie D, et al: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326-5334, 2008
2. Sackett DL, Rosenberg WM, Gray JA, et al: Evidence-based medicine: What it is and what it isn't. BMJ 312:71-72, 1996